If you’ve held Moderna shares for a while, could lock in a profit if you sold, and are looking to move on to other opportunities, you might consider at least trimming your position. Moderna (MRNA) reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs. In the 2024 presidential election’s latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme… Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company’s peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure.
Expanding beyond COVID is going to be key to Moderna stock being a good long-term investment. The company does have products in its pipeline that could be blockbusters, including its RSV vaccine (peak sales of up to $2.1 billion) and its vaccine for the cytomegalovirus (potentially $5 billion at its peak). But it will take years for sales from those products, assuming they obtain approval, to flow through to the business. Moderna (MRNA 7.48%) was a top stock to own during the early stages of the pandemic. The COVID-19 vaccine maker reached a market cap of nearly $200 billion at its peak in 2021. But nowadays, with revenue from its vaccine diminishing and no longer being a strong growth catalyst, investors have become bearish on the healthcare stock.
もくじ
Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers
Moderna is not the only company working on mRNA, but it is the company’s focus, and therefore it can put all its resources toward that technology. Moderna is working in other areas as well, including convert british pounds to danish kroner respiratory vaccines, oncology therapeutics, and rare disease therapeutics. Moderna (MRNA) shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker’s pipeline and cash position.
First, let’s consider all of the important points Moderna talked about during its annual R&D day — and why it’s making certain decisions. Lowering its R&D expenses and slashing certain programs will result in fewer products launched in the next few years. This is after — just last year — forecasting the launch of as many as 15 new products over the next five years. © 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
Financial Snapshot: Moderna’s Recent Earnings and Market Impacts
It won approval for its new respiratory syncytial virus (RSV) vaccine, reported positive data from trials of late-stage candidates, and even saw its shares climb about 20% in the first half of the year. While many investors might be excited about the company’s pipeline, the consensus of analysts how to become a cloud engineer is clearly concerned about its ability to commercialize these vaccines this decade. And as highlighted by the earnings forecast, Moderna may need to raise additional capital in the coming years in order to bring these new products to market. Personally, despite the stock plummeting in recent months, I’m still not convinced that this is the bottom, and an investment in Moderna could be dead money.
Major companies that are also popular short-selling stocks
You can find a company’s peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis. Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish. Crucially, Moderna’s reaffirmed focus on groundbreaking research and strategic endeavors, like the RSV vaccine expansion, predicates a future less reliant on pandemic-driven sales and more diversified across therapeutic developments and territories. Moreover, if confirmed, Kennedy’s stance and policies could exacerbate existing vaccine hesitancy, impacting both current and future vaccine uptake in the U.S.
- Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S.
- Hanseatic Management Services Inc. purchased a new stake in shares of Moderna during the second quarter worth about $48,000.
- To see all exchange delays and terms of use please see Barchart’s disclaimer.
- While stock price movement reflects these multilayered dynamics, the reality of managing expectations amidst scientific innovations cannot be overstated.
- Moderna approaches the development of vaccines and therapeutics using Messenger RNA (mRNA) technology.
In the meantime, the company is also working on developing other products, such as mRNA-3927, which is a treatment for propionic acidemia (an organic acid disorder). Its most promising product may be the personalized cancer vaccine it is working on with Merck, which is currently in phase 3 trials. It could potentially treat multiple cancers, including non-small cell lung cancer, melanoma, and other types of tumors. Moderna is projecting $4 billion in revenue this year, which factors in approval of its respiratory syncytial virus (RSV) vaccine, which the company anticipates should come within the first half of the year. The company is still working on a combination shot for COVID and the flu, which looks to still be part of its long-term strategy. If Moderna can replicate its COVID-19 success with other respiratory viruses like the flu and RSV, there’s a case to be made that shareholders will be rewarded over time.
Please bear with us as we address this and restore your personalized lists. I became a self-made millionaire by the age of 21, trading thousands of Penny Stocks – yep you read that right, Penny Stocks. Despite setbacks, key valuation metrics shed light on Moderna’s enduring market impact. With assets exceeding $15.8B against liabilities of roughly $3.88B, Moderna displays robust financial strength, characterized by ratios that underscore a robust current and quick ratio, indicating strong liquidity reserves.
As Moderna brings more products to the market, there will be additional opportunities to add to the position over time. Moderna approaches the development of vaccines and therapeutics using Messenger RNA (mRNA) technology. Put very simply, a vaccine utilizing mRNA technology teaches the body to make its own medicine.
Moderna has a lot of trials going on and may have a lot of potential sources of revenue in the future. But this isn’t a stock I’d buy today as there isn’t anything terribly exciting in its pipeline outside of its personalized cancer vaccine. But flu vaccines, COVID shots, and RSV vaccines may not be enough to make the business profitable in the long run. But if you’re ready to hold on for a few more years, it could turn out to be a wise move. (And buying the stock now, on the dip, could be a smart move too.) Moderna has five respiratory vaccines that have generated positive phase 3 data, and five non-respiratory candidates involved in pivotal studies. So there’s reason to be optimistic about the company’s 3 steps to calculate coinbase taxes 2021 updated product approval forecasts, and therefore its revenue potential down the road.
